Y-mAbs Therapeutics Future Growth
Future criteria checks 1/6
Y-mAbs Therapeutics's earnings are forecast to decline at 21.7% per annum while its annual revenue is expected to grow at 15.6% per year. EPS is expected to decline by 13.5% per annum. Return on equity is forecast to be 1.7% in 3 years.
Key information
-21.7%
Earnings growth rate
-13.5%
EPS growth rate
| Biotechs earnings growth | 20.7% |
| Revenue growth rate | 15.6% |
| Future return on equity | 1.7% |
| Analyst coverage | Good |
| Last updated | 05 Apr 2024 |
Recent future growth updates
Recent updates
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Mar 14
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Feb 17Y-mAbs Therapeutics: A Monoclonal Antibody Play
Jan 14We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
Nov 13We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Jul 16Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts
May 13Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%
Apr 17Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely
Mar 22We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully
Dec 13Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically
Aug 13Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers
Jul 12Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers
May 30Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?
May 12Y-mAbs Therapeutics (NASDAQ:YMAB) Is In A Good Position To Deliver On Growth Plans
Dec 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 128 | -62 | N/A | N/A | 3 |
| 12/31/2025 | 118 | -34 | -31 | -9 | 4 |
| 12/31/2024 | 98 | -23 | -33 | -17 | 6 |
| 12/31/2023 | 85 | -21 | -27 | -27 | N/A |
| 9/30/2023 | 93 | -19 | -28 | -28 | N/A |
| 6/30/2023 | 85 | -39 | -46 | -46 | N/A |
| 3/31/2023 | 75 | -74 | -64 | -64 | N/A |
| 12/31/2022 | 65 | -96 | -76 | -76 | N/A |
| 9/30/2022 | 43 | -134 | -102 | -101 | N/A |
| 6/30/2022 | 40 | -135 | -100 | -100 | N/A |
| 3/31/2022 | 40 | -117 | -96 | -96 | N/A |
| 12/31/2021 | 35 | -55 | -104 | -103 | N/A |
| 9/30/2021 | 46 | -38 | -87 | -86 | N/A |
| 6/30/2021 | 37 | -42 | -93 | -92 | N/A |
| 3/31/2021 | 26 | -60 | -102 | -101 | N/A |
| 12/31/2020 | 21 | -119 | -91 | -91 | N/A |
| 9/30/2020 | N/A | -123 | -99 | -98 | N/A |
| 6/30/2020 | N/A | -114 | -97 | -95 | N/A |
| 3/31/2020 | N/A | -91 | -84 | -82 | N/A |
| 12/31/2019 | N/A | -81 | -75 | -73 | N/A |
| 9/30/2019 | N/A | -72 | -63 | -62 | N/A |
| 6/30/2019 | N/A | -59 | -51 | -50 | N/A |
| 3/31/2019 | N/A | -52 | -48 | -48 | N/A |
| 12/31/2018 | N/A | -43 | -41 | -41 | N/A |
| 9/30/2018 | N/A | -38 | -34 | -34 | N/A |
| 6/30/2018 | N/A | -31 | -28 | -27 | N/A |
| 3/31/2018 | N/A | -24 | -19 | -19 | N/A |
| 12/31/2017 | N/A | -19 | -16 | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YMAB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: YMAB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: YMAB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: YMAB's revenue (15.6% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: YMAB's revenue (15.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: YMAB's Return on Equity is forecast to be low in 3 years time (1.7%).